Anthony Gregg Lapointe - 15 May 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Reporting relationship: Director
Issuer ticker: RIGL
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 20:49:29 UTC
Prior SEC filing: 23 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Raymond Furey (Attorney-in-Fact)

Key filing fact

Anthony Gregg Lapointe filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 19 May 2026.

Key facts

This page summarizes Anthony Gregg Lapointe's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 20:49.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001331860 Primary reporting owner

LAPOINTE ANTHONY GREGG

Relationship: Director
Address: RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RIGL transaction

Common Stock

Award

Transaction value
Shares: +5,750
Change %: +46%
Price: $0.000000^*
Shares after: 18,250
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.